Biogen Gets EU Nod for First Postpartum Depression Drug

Key Takeaways Biogen gained EU approval for Zurzuvae, the first postpartum depression drug in the region.Approval followed strong phase III SKYLARK results showing rapid, sustained symptom relief.Zurzuvae sales hit $46.4M in Q2 2025, up 68% sequentially, exceeding Biogen's internal expectations.Biogen (BIIB) announced that the European Commission (“EC”) has approved Zurzuvae (zuranolone) to treat postpartum depression (PPD) in adults after childbirth.Following this approval, Zurzuvae became the first and on ...